We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Journal Scan / Research · August 17, 2022

Impact of Trial Eligibility on Use of ICI-Based Combination Therapy in Patients With Metastatic RCC

Targeted oncology

 

Additional Info

Targeted oncology
Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy for Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility Criteria
Target Oncol 2022 Jul 01;17(4)475-482, Y Nemoto, H Ishihara, K Nakamura, H Tachibana, H Fukuda, K Yoshida, H Kobayashi, J Iizuka, H Shimmura, Y Hashimoto, K Tanabe, T Kondo, T Takagi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading